GO:1990406 CGRP receptor complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1990406 (CGRP receptor complex) is a cellular_component term describing a transmembrane, G protein-coupled signaling receptor complex recognized by calcitonin gene-related peptides (CGRP).
• The canonical CGRP receptor is a heterodimer of the class B GPCR calcitonin receptor-like receptor (CALCRL) and receptor activity-modifying protein 1 (RAMP1), which traffics CALCRL to the plasma membrane and defines CGRP pharmacology [4,5].
• CGRP receptor signaling proceeds mainly through Gs-mediated cAMP elevation and downstream PKA/CREB activation, with additional beta-arrestin-dependent and other pathways reported.
• The CGRP receptor complex is a validated therapeutic target in migraine, where small-molecule gepants and monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) block CGRP signaling [1,2,3].
• CGRP and the related peptide PACAP share and diverge in migraine pathophysiological roles, making receptor-complex specificity important for drug design [6,8].
• Structural and pharmacological studies, including cryo-EM of related class B GPCR/RAMP complexes, inform rational targeting of the CGRP receptor complex [4,7].
Description
The CGRP receptor complex (GO:1990406) is defined in the Gene Ontology as a transmembrane, G protein-coupled signaling receptor complex recognized by calcitonin gene-related peptides (CGRP). It sits at the interface of neuropeptide physiology and migraine pharmacology, and it is one of the best-characterized class B GPCR signaling assemblies in human biology [1,4]. Because CGRP is a potent vasodilatory and nociceptive neuropeptide, the receptor complex that mediates its effects has become a central target for both acute and preventive migraine therapies [1,2]. Understanding its composition, assembly, and signaling is therefore essential for researchers in neuroscience, vascular biology, and drug discovery [1,5]. The canonical CGRP receptor is a heterodimer formed by calcitonin receptor-like receptor (CALCRL) and receptor activity-modifying protein 1 (RAMP1) [4,5]. RAMP1 is required for efficient trafficking of CALCRL to the cell surface and for high-affinity CGRP binding, and it defines the pharmacological profile that distinguishes CGRP receptors from related adrenomedullin receptors. This heterodimeric architecture is a hallmark of family B GPCR/RAMP receptor complexes and explains why targeting the complex, rather than CALCRL alone, has been a productive therapeutic strategy. For researchers, GO:1990406 provides a precise annotation for the receptor assembly that transduces CGRP signals. It is relevant to migraine pathophysiology, to the mechanism of action of gepants and anti-CGRP monoclonal antibodies, and to comparative studies of CGRP versus PACAP signaling [1,2,6,8]. The sections below summarize the definition, composition, molecular mechanism, key genes, disease links, and experimental methods used to study this complex.
CGRP receptor complex At A Glance
| GO ID | GO:1990406 |
|---|---|
| GO term | CGRP receptor complex |
| Ontology | cellular_component |
| Synonym | Calcitonin-gene-related peptide receptor complex; calcitonin gene-related polypeptide receptor complex; CGRP-R complex |
| Major function | Transmembrane G protein-coupled signaling receptor complex recognized by CGRP |
| Canonical composition | CALCRL (calcitonin receptor-like receptor) and RAMP1 (receptor activity-modifying protein 1) heterodimer [4,5] |
| Primary signaling | Gs-mediated cAMP elevation with downstream PKA/CREB activation |
| Therapeutic relevance | Target of gepants and anti-CGRP monoclonal antibodies in migraine [1,2,3] |
What Is GO:1990406?
GO:1990406 describes a transmembrane, G protein-coupled signaling receptor complex that is recognized by calcitonin gene-related peptides (CGRP). In practice, this term annotates the functional receptor assembly through which CGRP elicits intracellular signals, most commonly the CALCRL/RAMP1 heterodimer at the plasma membrane [4,5]. The term is a cellular_component annotation, meaning it describes where the receptor complex resides and what it is composed of, rather than a single molecular function or biological process.
Why Is CGRP receptor complex Important in Cell Biology?
The CGRP receptor complex is important because it is the primary signaling assembly through which CGRP exerts its effects in the trigeminovascular system, and it is the direct or indirect target of several approved migraine therapies [1,2]. Blocking this complex, either with small-molecule CGRP receptor antagonists (gepants) or with monoclonal antibodies that bind CGRP ligand or the receptor, reduces migraine frequency and severity in clinical practice [1,3]. Because the complex is a heterodimer of CALCRL and RAMP1, its pharmacology is shaped by RAMP1, which has implications for drug selectivity and for understanding why some patients respond differently to CGRP-targeted therapies [4,5].
• Validated drug target in migraine: gepants and anti-CGRP monoclonal antibodies act on or around this complex [1,2,3].
• Defines CGRP pharmacology through the CALCRL/RAMP1 heterodimer, distinguishing it from adrenomedullin receptors.
• Central to trigeminovascular nociception and neurogenic inflammation in migraine [1,2].
• Provides a model for class B GPCR/RAMP complex assembly and signaling [4,5].
• Relevant to comparative studies of CGRP and PACAP in migraine pathophysiology [6,8].
• Informs structural biology of peptide-bound class B GPCR complexes, including cryo-EM studies of related receptors.
• Supports biomarker and pharmacodynamic research in headache medicine [1,3].
• Guides development of next-generation antagonists with improved selectivity and delivery.
Structure and Composition of CGRP receptor complex
CALCRL: the class B GPCR core
In simple terms: CALCRL is the main receptor protein that CGRP binds to.
CALCRL (calcitonin receptor-like receptor) is a class B G protein-coupled receptor that forms the signaling core of the CGRP receptor complex [4,5]. On its own, CALCRL is inefficiently trafficked and does not display canonical CGRP pharmacology; it requires a RAMP partner to reach the cell surface and to bind CGRP with high affinity. This dependence on heterodimerization is a defining feature of the CGRP receptor complex annotated by GO:1990406 [1,4].
RAMP1: the specificity and trafficking subunit
In simple terms: RAMP1 is the partner protein that helps CALCRL get to the cell surface and makes it respond to CGRP.
Receptor activity-modifying protein 1 (RAMP1) is a single-transmembrane-domain accessory protein that associates with CALCRL to form the canonical CGRP receptor [4,5]. RAMP1 promotes CALCRL trafficking to the plasma membrane and confers CGRP selectivity, distinguishing the CGRP receptor from adrenomedullin-preferring CALCRL/RAMP2 or CALCRL/RAMP3 complexes. Because RAMP1 shapes ligand recognition, it is a key determinant of CGRP receptor pharmacology and a focus of antagonist design.
Heterodimer assembly at the plasma membrane
In simple terms: The two proteins come together at the cell surface to form the working receptor.
The functional CGRP receptor complex is assembled as a CALCRL/RAMP1 heterodimer at the plasma membrane [4,5]. Assembly is required for G protein coupling and for signal transduction in response to CGRP, and the complex is the entity recognized by CGRP and by receptor-targeting drugs [1,4]. This heterodimeric organization is characteristic of family B GPCR/RAMP receptor complexes and is central to the GO:1990406 annotation [1,4].
Related receptor complexes and structural context
In simple terms: Similar receptors built from related proteins help scientists understand how the CGRP receptor works.
Structural and pharmacological studies of related class B GPCR/RAMP complexes, including cryo-EM analysis of the human amylin 1 receptor bound to CGRP and Gs protein, provide a framework for understanding how CGRP engages its receptor and activates G proteins. These studies help explain the molecular basis of ligand recognition and G protein coupling in the CGRP receptor family. Comparative analysis of CGRP and PACAP receptor systems further highlights shared and distinct features relevant to migraine biology [6,8].
Key Genes Involved in GO:1990406 CGRP receptor complex
The following genes and proteins are central to the composition, regulation, and pharmacology of the CGRP receptor complex (GO:1990406).
| Gene | Major Role | Research Relevance |
|---|---|---|
| CALCRL | Class B GPCR core of the CGRP receptor complex | Primary receptor subunit; target of receptor antagonists and antibody approaches [4,5] |
| RAMP1 | Accessory protein that traffics CALCRL and confers CGRP selectivity | Determines pharmacology and is a key selectivity determinant |
| RAMP2 | Related RAMP that partners with CALCRL for adrenomedullin-preferring receptors | Comparative control for CGRP receptor specificity studies |
| RAMP3 | Related RAMP that partners with CALCRL for adrenomedullin-preferring receptors | Comparative control for CGRP receptor specificity studies |
| CALCA | Encodes CGRP peptide precursor (calcitonin gene-related peptide) | Ligand for the CGRP receptor complex; target of ligand-blocking antibodies [1,2] |
| CALCB | Encodes beta-CGRP peptide | Related ligand with potential relevance to migraine biology |
| ADCYAP1 | Encodes PACAP, a related neuropeptide | Used in comparative studies of CGRP versus PACAP signaling [6,8] |
| ADCYAP1R1 | PACAP receptor | Comparator for CGRP receptor complex signaling studies [6,8] |
| GNAS | Encodes Gs alpha subunit | Mediates cAMP signaling downstream of the CGRP receptor complex |
| PRKACA | Catalytic subunit of PKA | Downstream effector of cAMP signaling from the CGRP receptor complex |
| CREB1 | Transcription factor activated by cAMP/PKA | Readout of CGRP receptor complex signaling |
| ARRB1 | Beta-arrestin 1 | Participates in desensitization and alternative signaling of GPCRs including CGRP receptor |
| ARRB2 | Beta-arrestin 2 | Participates in desensitization and alternative signaling of GPCRs including CGRP receptor |
| GNAI1 | Gi alpha subunit | Potential contributor to non-Gs signaling pathways reported for CGRP receptors |
| GNAQ | Gq alpha subunit | Potential contributor to non-Gs signaling pathways reported for CGRP receptors |
| CALCR | Calcitonin receptor, related class B GPCR | Comparator for understanding CGRP receptor complex evolution and pharmacology |
| CRCP | Calcitonin receptor-stimulating peptide-related biology | Context for related calcitonin family peptide signaling |
How Is CGRP receptor complex Regulated?
CGRP receptor complex signaling is regulated at multiple levels. Ligand availability is controlled by CGRP expression and release from trigeminal neurons, and receptor responsiveness can be modulated by RAMP1 expression levels, which influence CALCRL trafficking and CGRP binding [1,4]. At the signaling level, Gs-mediated cAMP production is subject to desensitization and regulation by beta-arrestins and other GPCR regulatory mechanisms. Comparative studies of CGRP and PACAP pathways indicate that these neuropeptide systems can be regulated independently or in shared circuits relevant to migraine [6,8].
CGRP receptor complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CALCRL | Migraine and CGRP-mediated neurovascular signaling | CALCRL knockout or knockdown cell models; receptor antagonist assays [1,4] |
| RAMP1 | Migraine pharmacology and CGRP receptor selectivity | RAMP1 knockout or overexpression models to test CGRP responses |
| CALCA | CGRP ligand availability in migraine | CALCA knockout or knockdown models to assess ligand-dependent signaling [1,2] |
| ADCYAP1 | PACAP-related migraine biology | ADCYAP1 knockout models for comparative CGRP/PACAP studies [6,8] |
| GNAS | cAMP signaling downstream of CGRP receptor | GNAS perturbation models to dissect Gs-dependent signaling |
Migraine and headache disorders
The CGRP receptor complex is a central mediator of migraine pathophysiology, and CGRP-targeted therapies, including receptor antagonists (gepants) and monoclonal antibodies, are effective for migraine prevention and acute treatment [1,2,3]. Clinical success of these agents validates the receptor complex as a therapeutic node and supports ongoing research into patient selection and combination strategies.
Neurogenic inflammation and trigeminovascular activation
CGRP released from trigeminal neurons acts on the CGRP receptor complex to promote vasodilation and nociceptive signaling, contributing to neurogenic inflammation in migraine [1,2]. Understanding how the receptor complex is assembled and regulated helps explain how blocking CGRP signaling reduces headache burden [1,4].
Comparative neuropeptide biology: CGRP versus PACAP
PACAP is another neuropeptide implicated in migraine, and studies comparing CGRP and PACAP pathways have revealed shared and independent roles in migraine pathophysiology [6,8]. These comparisons are important for interpreting the specificity of CGRP receptor complex targeting and for developing broader therapeutic strategies [6,8].
From CGRP receptor complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CALCRL abolish CGRP-induced cAMP signaling? | CALCRL knockout cell line [4,5] |
| Does RAMP1 determine CGRP versus adrenomedullin selectivity? | RAMP1 knockout or RAMP1/RAMP2 swap models |
| Can a point mutation in CALCRL alter ligand binding? | Point-mutation knock-in of CALCRL [4,7] |
| How does tagged CALCRL behave in trafficking assays? | Tagged knock-in of CALCRL for imaging |
| Does overexpression of RAMP1 enhance CGRP responses? | RAMP1 overexpression cell model [4,5] |
| Which downstream effectors mediate CGRP signaling? | Knockout or knockdown of GNAS, PRKACA, or ARRB1/2 |
How to Study the CGRP receptor complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| cAMP assay | Gs-mediated cAMP accumulation | Measure CGRP receptor complex activation and antagonist potency |
| Radioligand binding | Ligand affinity and receptor selectivity | Characterize CALCRL/RAMP1 pharmacology |
| Cryo-EM | Three-dimensional structure of receptor-ligand-G protein complexes | Understand class B GPCR/RAMP architecture |
| Western blot | Protein expression of CALCRL, RAMP1, and signaling effectors | Validate knockout or overexpression models [4,5] |
| Immunofluorescence | Subcellular localization and trafficking | Assess CALCRL/RAMP1 membrane assembly |
| qPCR | mRNA levels of receptor components | Confirm genetic manipulation and expression changes |
| CRISPR knockout screening | Gene requirement for CGRP receptor signaling | Identify modifiers of receptor complex function [4,5] |
| Comparative PACAP/CGRP assays | Shared versus distinct neuropeptide signaling | Interpret migraine-relevant pathway specificity [6,8] |
cAMP and signaling assays
Because the CGRP receptor complex signals primarily through Gs-mediated cAMP production, cAMP accumulation assays are a standard method to measure receptor activation and to test antagonists. These assays can be combined with PKA and CREB readouts to map downstream signaling.
Binding and pharmacological profiling
Radioligand binding and competition assays using CGRP or CGRP receptor antagonists are used to characterize receptor affinity and selectivity, particularly in the context of CALCRL/RAMP1 versus related RAMP complexes. Such profiling is essential for evaluating gepants and antibody-based approaches [1,4].
Structural biology and cryo-EM
Cryo-EM and related structural approaches have been used to determine how class B GPCR/RAMP complexes, including the amylin 1 receptor bound to CGRP and Gs, recognize peptide ligands and couple to G proteins. These structures provide templates for understanding CGRP receptor complex architecture.
Genetic and comparative models
Knockout, knockdown, and comparative studies of CGRP and PACAP systems help dissect the specific contribution of the CGRP receptor complex to migraine-related phenotypes [6,8]. Such models are also useful for testing whether receptor components are causally involved in signaling responses [4,5].
How CRISPR Can Be Used to Study GO:1990406 CGRP receptor complex
Knockout
CRISPR knockout of CALCRL or RAMP1 can be used to eliminate CGRP receptor complex function and to test whether CGRP-induced signaling depends on the canonical heterodimer [4,5]. Such models are useful for validating receptor-specific responses and for comparing CGRP with related neuropeptide pathways [6,8].
Point Mutation
Point mutations in CALCRL or RAMP1 can be introduced to probe ligand-binding determinants, G protein coupling interfaces, or residues implicated in receptor activation [4,7]. These models help link structural predictions to functional pharmacology.
Knock-in
Knock-in of tagged CALCRL or RAMP1 allows tracking of receptor complex trafficking, localization, and interaction partners in native-like contexts. Tagged knock-in models are valuable for imaging and proteomic studies of the CGRP receptor complex.
Overexpression
Overexpression of CALCRL and RAMP1 can amplify CGRP receptor complex signaling for biochemical and pharmacological assays [4,5]. This approach is often used to study downstream cAMP/PKA/CREB responses and to test antagonist efficacy.
How EDITGENE Supports CGRP receptor complex Research
Researchers studying CGRP receptor complex-related genes often need to determine whether a candidate gene is causally involved in receptor assembly, ligand recognition, or downstream signaling. Rigorous causal testing requires well-controlled genetic models, including knockout, point-mutation, knock-in, and overexpression cell lines, as well as functional screening and bioinformatics support.
Contact EDITGENE today to design your custom CRISPR model for CGRP receptor complex research.
Frequently Asked Questions About CGRP receptor complex
What is the CGRP receptor complex?
The CGRP receptor complex (GO:1990406) is a transmembrane, G protein-coupled signaling receptor complex recognized by calcitonin gene-related peptides (CGRP).
What genes are involved in the CGRP receptor complex?
The canonical complex is formed by CALCRL and RAMP1, with related RAMPs (RAMP2, RAMP3) defining other receptor complexes [4,5].
What is GO:1990406?
GO:1990406 is the Gene Ontology identifier for the CGRP receptor complex, a cellular_component term.
How does the CGRP receptor complex signal?
It signals primarily through Gs-mediated cAMP elevation and downstream PKA/CREB activation, with additional regulatory pathways reported.
Why is the CGRP receptor complex important in migraine?
It mediates CGRP effects in the trigeminovascular system and is targeted by effective migraine therapies, including gepants and anti-CGRP antibodies [1,2,3].
What drugs target the CGRP receptor complex?
Small-molecule CGRP receptor antagonists (gepants) and monoclonal antibodies against CGRP or its receptor are used in migraine treatment [1,3].
How is the CGRP receptor complex studied?
Common methods include cAMP assays, radioligand binding, cryo-EM, immunofluorescence, and CRISPR-based genetic models [4,5,7].
What is the difference between CGRP and PACAP in migraine?
CGRP and PACAP are related neuropeptides with shared and independent roles in migraine pathophysiology, which affects therapeutic targeting strategies [6,8].
Can CRISPR be used to study the CGRP receptor complex?
Yes, CRISPR knockout, point-mutation, knock-in, and overexpression models can be used to dissect receptor complex function [4,5].
What cell models are useful for CGRP receptor research?
Knockout, point-mutation, tagged knock-in, and overexpression cell lines for CALCRL and RAMP1 are useful for functional and pharmacological studies [4,5].
Conclusion
The CGRP receptor complex (GO:1990406) is a well-defined cellular_component term describing the transmembrane GPCR assembly that mediates CGRP signaling, canonically through the CALCRL/RAMP1 heterodimer [1,4]. Its central role in migraine pathophysiology and its validation as a therapeutic target make it a high-priority subject for pharmacological, structural, and genetic research [1,2,3]. Continued work using CRISPR models, signaling assays, and structural approaches will refine our understanding of how this complex is assembled, regulated, and best targeted in disease [4,5,7].
References
- 1. Russo AF et al.. 2023. CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond.. Physiol Rev 103(2):1565-1644 PMID: 36454715
- 2. Puledda F et al.. 2023. Migraine: from pathophysiology to treatment.. J Neurol 270(7):3654-3666 PMID: 37029836
- 3. Pellesi L et al.. 2024. Combining treatments for migraine prophylaxis: the state-of-the-art.. J Headache Pain 25(1):214 PMID: 39639191
- 4. Moore EL et al.. 2012. Targeting a family B GPCR/RAMP receptor complex: CGRP receptor antagonists and migraine.. Br J Pharmacol 166(1):66-78 PMID: 21871019
- 5. Cottrell GS. 2019. CGRP Receptor Signalling Pathways.. Handb Exp Pharmacol 255:37-64 PMID: 30151722
- 6. Kuburas A et al.. 2023. Shared and independent roles of CGRP and PACAP in migraine pathophysiology.. J Headache Pain 24(1):34 PMID: 37009867
- 7. Cao J et al.. 2024. Cryo-EM Structure of the Human Amylin 1 Receptor in Complex with CGRP and Gs Protein.. Biochemistry 63(9):1089-1096 PMID: 38603770
- 8. Pietra AD et al.. 2025. PACAP versus CGRP in migraine: From mouse models to clinical translation.. Cephalalgia 45(9):3331024251364242 PMID: 40931761
